A randomised phase II study of carmustine alone or in combination with tomour necrosis factor in patients with advanced melanoma
| Autor: | A. L. Jones, J. Moore, John L. Millar, Alison Lorentzos, Mary O'Brien, Angela Hanrahan, C. Viner, Martin Gore |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Necrosis Adolescent medicine.medical_treatment Phases of clinical research Toxicology Gastroenterology Drug Administration Schedule Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Pharmacology (medical) Infusions Intravenous Melanoma Aged Pharmacology Chemotherapy Carmustine Tumor Necrosis Factor-alpha business.industry Drug Synergism Immunotherapy Middle Aged medicine.disease Recombinant Proteins Surgery Cytokine Oncology Toxicity Drug Evaluation Female medicine.symptom business medicine.drug |
| Zdroj: | Cancer Chemotherapy and Pharmacology. 30:73-76 |
| ISSN: | 1432-0843 0344-5704 |
| DOI: | 10.1007/bf00686489 |
| Popis: | Laboratory data suggest a synergistic interaction between carmustine (BCNU) and tumour necrosis factor (TNF) in melanoma. We therefore studied the activity of 200 mg/m2 BCNU given alone or in combination with 88 micrograms/m2 recombinant human TNF-alpha (rhTNF alpha) as a daily i.v. infusion for 5 days at 48-day intervals to patients with metastatic melanoma. In this randomised phase II trial, the rate of response to BCNU alone was 20% [95% confidence interval (CI), 2%-38%], and this was not improved by the addition of TNF (response rate, 10.5%; 95% CI, 1.3%-33%). Toxicity was higher in the combination arm, and there was no difference in survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink